Exploring alternate targets for inhibition of virus infection by PPI disruption
探索通过 PPI 破坏抑制病毒感染的替代靶点
基本信息
- 批准号:10356929
- 负责人:
- 金额:$ 21.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-22 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdherenceAdvanced DevelopmentAffectAmino AcidsAntiviral AgentsAntiviral TherapyAreaBasic ScienceBindingBinding SitesBiological AssayCOVID-19 pandemicCell physiologyCellsChemicalsCommunicable DiseasesDevelopmentDisease OutbreaksDrug TargetingEffectivenessEventExhibitsGeneticGenomeHealthHot SpotHumanInfectionInfluenza A virusIntegration Host FactorsLibrariesLife Cycle StagesLigand BindingMedicalMiddle East Respiratory Syndrome CoronavirusMolecular ConformationNatureOrganismPersonal SatisfactionPharmaceutical PreparationsPhenotypePopulationProcessPropertyProteinsProteomeRecurrenceResistanceTestingTherapeuticVaccinationValidationViralViral ProteinsViral Respiratory Tract InfectionVirusVirus DiseasesVirus InhibitorsVirus ReplicationZoonosesantiviral drug developmentbaseburden of illnesseconomic impactinhibitorinnovationobligate intracellular parasitepandemic diseasepathogenpreventprotein protein interactionprototyperespiratory virusscreeningsmall moleculetherapeutically effectivetraffickingtransmission processviral resistance
项目摘要
Project Summary/Abstract
The current epidemics of SARS CoV2 is an acute reminder that infectious diseases remain an enormous threat
to the well-being and prosperity of human populations, and respiratory viral infections are the leading cause of
burden of disease world-wide. Indeed, given their airborne mode of transmission, respiratory viruses are prone
to rapid and often initially unrecognized spread with potential for pandemics resulting in significant health,
societal, and economic impact. Despite medical progress and vaccination, many infectious diseases have
emerged or re-emerged in the second half of the twentieth century. Recent events of viral zoonoses such as the
influenza A virus 2009 pandemic, the Middle East Respiratory Syndrome (MERS) coronavirus outbreak, and of
course the ongoing CoVID19 pandemic dramatically emphasize the need to expand basic research on such
pathogens in order to develop new antiviral therapies with low potential for therapeutic escape. Despite constant
efforts of diversification of classes of inhibitors, recurrent emergence of viral resistance towards existing
conventional antiviral drugs emphasizes the need for alternative targets less amenable to therapeutic escape,
especially non-viral targets such as host cellular factors that promote virus multiplication.
Viruses depend on their ability to hijack and control the cellular machinery to multiply and spread through
organisms and populations. Hence, compounds inhibiting the virus’s ability to interact with, and rewire, the host
cellular machinery are the most promising candidates for host-directed anti-viral therapeutics. Here we propose
the development of a systematic strategy to identify inhibitors of viral-host protein-protein interactions. Applying
it to influenza A viruses, we will pioneer our discovery pipeline using virus-host PPI involved in the trafficking of
viral components or in viral escape of host cell restriction, processes that are strongly dependent on the
interactions that the viral proteins engage with host factors. Chemical compounds disrupting biologically-
validated PPIs will be screened using a multi-parameter toolkit of assays. The anti-viral potential of validated
PPI-inhibiting compounds will be determined using influenza A virus strains of
项目总结/摘要
目前SARS CoV 2的流行是一个严重的提醒,传染病仍然是一个巨大的威胁
人类的福祉和繁荣,呼吸道病毒感染是导致
世界范围内的疾病负担。事实上,考虑到呼吸道病毒的空气传播方式,
迅速和往往最初未被认识到的传播,有可能导致严重的健康问题,
社会和经济影响。尽管医学进步和疫苗接种,许多传染病仍然存在。
在世纪后半叶出现或重新出现。最近发生的病毒性人畜共患病事件,
2009年甲型流感病毒大流行、中东呼吸综合征冠状病毒爆发,以及
当然,正在进行的CoVID 19大流行极大地强调了扩大对这种疾病的基础研究的必要性。
病原体,以开发新的抗病毒疗法,治疗逃逸的可能性低。尽管不断
抑制剂种类多样化的努力,病毒对现有药物的耐药性的反复出现,
常规的抗病毒药物强调了对不太适合治疗逃逸的替代靶点的需要,
特别是非病毒靶,例如促进病毒增殖的宿主细胞因子。
病毒依赖于它们劫持和控制细胞机器的能力来繁殖和传播
生物和人口。因此,抑制病毒与宿主相互作用和重新连接的能力的化合物
细胞机制是宿主导向的抗病毒治疗剂的最有希望的候选物。在这里我们建议
开发一种系统的策略来鉴定病毒-宿主蛋白质-蛋白质相互作用的抑制剂。应用
它的甲型流感病毒,我们将开拓我们的发现管道使用病毒宿主PPI参与贩运,
病毒组分或病毒逃避宿主细胞限制,强烈依赖于病毒组分的过程,
病毒蛋白与宿主因子的相互作用。化学化合物在生物学上破坏-
将使用多参数检测工具包筛选经验证的PPI。经验证的抗病毒潜力
PPI抑制化合物将使用以下甲型流感病毒株测定:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael A Calderwood其他文献
Michael A Calderwood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael A Calderwood', 18)}}的其他基金
Exploring alternate targets for inhibition of virus infection by PPI disruption
探索通过 PPI 破坏抑制病毒感染的替代靶点
- 批准号:
10217383 - 财政年份:2021
- 资助金额:
$ 21.84万 - 项目类别:
Development of an OPTogenetic InteractoMics Assay (OPTIMA)
OPTogenic InteractoMics 检测 (OPTIMA) 的开发
- 批准号:
10057519 - 财政年份:2020
- 资助金额:
$ 21.84万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 21.84万 - 项目类别:
Fellowship Programs














{{item.name}}会员




